Congenital Heart DiseasesFAST-CMRNCT07613398
An International Multicenter, Multivendor Evaluation of the Free-Running Framework for Cardiac Function
An observational study of Congenital Heart Diseases and Cardiac Diseases, run by Matthias Stuber at 20 sites in 10 countries.
Trial summary
This project aims to evaluate a new cardiac MRI technique called the Free-Running Framework (FRF), which could simplify and accelerate the process of acquiring cardiac images. The investigators want to verify whether this method can provide functional heart measurements comparable to those obtained with traditional… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Congenital Heart Diseases, Cardiac Diseases
- How many people
- 300 participants
- Where
- 20 sitesin 10 countries
- Study dates
- Jun 2026to Sep 2030
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: This study will prospectively include 300 patients (~15-20 per site) with known or suspected cardiac disease who are referred for a clinically indicated CMR scan as part of their routine clinical work-up.
Who may be able to join
- Diagnosed with cardiac disease of any complexity and scheduled for a clinical cardiac MRI on a clinical 1.5T MRI scanner
- Able to understand and provide written informed consent or, for minors, ability to provide assent with written consent from a parent/legal representative, per local law and site policy prior to the study
- Ability to undergo MRI without contraindications
- Agrees to be informed in the event of incidental findings
Who cannot join
- Severe claustrophobia preventing MRI completion
- Presence of non-MRI compatible implants (e.g., pacemakers, certain metallic implants)
- Contraindications to the intravenous contrast agent
- Movement disorders or inability to remain still during the scan
Trial locations and contacts
20 sites in 10 countries. Contact the study team or a site near you to ask about taking part.
20 sites in 10 countries
United States9 sites
Emory University
Atlanta, Georgia, 30322
John Oshinski, PhD, +1 404-727-5894, jnoshin@emory.edu
Boston's Children Hospital
Boston, Massachusetts, 02115
Andrew Powell, MD, +1 617-355-2079, andrew.powell@cardio.chboston.org
Ann & Robert H Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611
Joshua D. Robinson, MD, +1 312-227-4638, jdrobinson@luriechildrens.org
Ohio State University
Columbus, Ohio, 43210
Yuchi Han, MD, +1 614-292-6446, yuchi.han@osumc.edu
UT Southwestern Medical Center
Dallas, Texas, 75390
Franz Gerald Greil, MD, PhD, +1 214-648-3111, gerald.greil@utsouthwestern.edu
University of California, Los Angeles
Los Angeles, California, 90095
Kim-Lien Nguyen, MD, +1 (310) 825-1234, KimLienNguyen@mednet.ucla.edu
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
Mark Fogel, MD, +1 215-590-3534, fogel@email.chop.edu
Mayo Clinic
Rochester, Minnesota, 55902
Tim Leiner, MD, PhD, +1 507-284-2511, leiner.tim@mayo.edu
Washington University in St. Louis
St Louis, Missouri, 63130
Pamela Woodard, MD, +1 314-747-3386, woodardp@nospam.wustl.edu
Germany3 sites
Charité - Universitätsmedizin Berlin
Berlin, State of Berlin, 10117
Sebastian Kelle, MD, PhD, +493045931182, sebastian.kelle@dhzc-charite.de
University of Bonn
Bonn, North Rhine-Westphalia, 53113
Julian Luetkens, MD, PhD, +49 228 287 19860, Julian.Luetkens@ukbonn.de
Cologne University Medical Center
Cologne, North Rhine-Westphalia, 50931
David Maintz, MD, PhD, +49 221 478-82035, david.maintz@uk-koeln.de
Australia1 site
University of Melbourne
Melbourne, Victoria, 3010
Ruth Lim, MD, +61 3 9035 5511, ruthplim74@gmail.com
Colombia1 site
Fundacion Cardioinfantil-LaCardio
Bogotá, Capital District, 111156
Carlos Guerrero, MD, +57 (601) 744 2000, ceguerrero@lacardio.org
Italy1 site
Università Cattolica - Fondazione Policlinico Gemelli IRCCS
Rome, Lazio, 00168
Luigi Natale, MD, +971 56 666 0984, luigi.natale@unicatt.it
Japan1 site
Mie University
Tsu, Mie-ken, 514-8507
Hajime Sakuma, MD, PhD, +81 59 231 5029, sakuma@med.mie-u.ac.jp
Netherlands1 site
Maastricht University Medical Center
Maastricht, Limburg, 6229 HX
Robert J. Holtackers, PhD, +31 43 387 49 10, rob.holtackers@mumc.nl
Singapore1 site
National University of Singapore
Singapore, Singapore, 119275
Liang Zhong, PhD, +65 67042237, gmszl@nus.edu.sg
South Africa1 site
University of Cape Town
Cape Town, Western Cape, 7700
Ntobeko Ntusi, MD, PhD, +27 21 406 6358, ntobeko.ntusi@uct.ac.za
United Kingdom1 site
King's College London
London, London, WC2R2LS
Amedeo Chiribiri, MD, PhD, +44 20 7188 8259, amedeo.chiribiri@kcl.ac.uk
About this study
Official title: Assessment and Validation of the Established Free-Running Framework for Cardiac Function by Magnetic Resonance Imaging (FAST-CMR): An International Multi-Center, Multi-Vendor Study at 1.5T
This project aims to evaluate a new cardiac MRI technique called the Free-Running Framework (FRF), which could simplify and accelerate the process of acquiring cardiac images. The investigators want to verify whether this method can provide functional heart measurements comparable to those obtained with traditional methods. More specifically, the goal of the study is to compare the measurements obtained with FRF to those obtained with standard sequences, to ensure they match and that this new approach can be reliably used in clinical practice. The FRF technique works differently from standard cardiac MRI. In standard exams, patients are asked to hold their breath several times and small electrodes (ECG) are used to monitor the heartbeat during the scan. These steps are needed to get clearer images of the heart as it moves. With FRF, these steps are no longer necessary: the scan is performed while patients' breath normally and without ECG monitoring. In addition, standard MRI takes multiple 2D slices of the heart, one after another. The FRF method instead captures a 3D image of the entire heart in one go, which can improve the consistency of the exam and reduce errors when doctors analyze the images later. This is all possible because the FRF method records data continuously and then organizes the images afterward based on how participants heart and breathing were moving during the exam. This helps the imager to get clear images of the heart, even without breath-holding or ECG monitoring. This project is aimed at individuals with heart disease who require cardiac MRI exams to monitor their health status (age ≥ 18 years) and are able to clearly understand the instructions provided by the research team. The investigators have already conducted small-scale technical and feasibility studies using FRF. These studies have shown that FRF is easy to use, faster than traditional methods, and provides image quality comparable to standard imaging techniques. The investigators now wish to evaluate its use in a clinical setting. More specifically, the investigators need to verify that FRF provides the same essential diagnostic information as standard techniques, so that it can be reliably used in future patient care. A maximum of 300 participants will be included in the investigation of this MRI technique between 2026 and 2031. This is a multi-center study, conducted internationally across 18 centers.
This project is being carried out in compliance with Swiss legislation. The investigators follow all internationally recognized guidelines. The competent ethics committee has reviewed and approved this project.
Read the detailed description
Cardiovascular disease remains the leading cause of death in industrialized nations. While a range of diagnostic tools exists for cardiovascular disease detection and monitoring, magnetic resonance imaging (MRI) remains the only modality that enables a safe, non-invasive assessment of the heart without exposure to ionizing radiation. MRI allows for a comprehensive evaluation of cardiac anatomy, function, myocardial tissue characterization, and blood flow quantification, making it a powerful tool for cardiovascular diagnostics.
Despite strong clinical evidence supporting its utility, cardiac MRI (CMR) remains underutilized, primarily due to the length and complexity of a traditional CMR exam. Several factors contribute to the length and complexity of a standard CMR exam. First, a standard CMR protocol relies heavily on two-dimensional (2D) image acquisitions, each requiring manual slice planning by an experienced technologist-a process that is both time consuming and highly dependent on operator expertise. Second, traditional image acquisition requires electrocardiogram (ECG) triggering to synchronize with the cardiac cycle, requiring additional setup and potentially introducing errors if the ECG signal is suboptimal. Finally, most conventional sequences rely on repeated patient breath-holding to minimize respiratory motion artifacts, which can be particularly challenging for individuals with severe cardiovascular disease, congenital anomalies, or limited compliance. Even for highly skilled personnel, this process is timeconsuming and inefficient. Consequently, a significant portion of the patient's time in the scanner is spent on preparation and planning rather than actual image acquisition, leading to prolonged exam durations and increased healthcare costs.
Given these challenges, there is a strong need for simplified, automated, and time-efficient CMR acquisitions. In response to this challenge, the investigators research group has developed an innovative "free-running framework" (FRF)-a set of MRI methods that continuously acquire threedimensional (3D) image data across the entire cardiac cycle and throughout free breathing, irrespective of cardiac or respiratory motion. Unlike conventional CMR sequences that require separate, prospectively planned acquisitions for each imaging plane and time point, FRF employs continuous, self-navigated data acquisition. This eliminates the need for complex slice planning and enables retrospective reconstruction of cardiac motion, ensuring that imaging is both standardized and independent of user expertise. By leveraging advanced motion-resolved reconstruction algorithms developed by the investigators group, the investigators can derive both cardiac and respiratory motion from a single dataset, providing a fully automated, 3D whole-heart imaging approach.
Once diagnosed, patients with cardiac diseases often require lifelong monitoring and repeated imaging assessments to guide treatment decisions and evaluate disease progression. This makes a non-ionizing imaging modality like CMR admirable. Nonetheless, the prolonged scan durations and intricate manual planning associated with traditional CMR limit its accessibility and practical feasibility. By eliminating the need for slice planning and reducing scan complexity, FRF has the potential to significantly improve imaging for cardiac disease patients by:
- Standardizing imaging: producing user-independent results robust to anatomical variations.
- Reducing scan times: without compromising diagnostic information.
- Improving accessibility: enabling easier adoption in centers with less experienced technologists.
The feasibility of FRF has been demonstrated in experimental, pre-clinical, and small observational clinical studies, with no observed adverse effects. This study aims to evaluate its clinical feasibility and efficiency in real-world cardiac disease patients across multiple cardiac institutions, serving as a precursor for larger validation studies and eventual clinical implementation. This study will provide the first systematic clinical evaluation of 3D FRF across multiple cardiac institutions in cardiac disease patients, assessing both its technical feasibility and potential workflow benefits in a real-world setting. In particular, this study will:
- Evaluate whether diagnostic information from FRF matches or exceeds standard CMR.
- Assess the efficiency gains and the impact of automated, self-navigated imaging on scan duration and patient comfort.
If successful, this study will lay the groundwork for future multi-center validation clinical trial studies and eventual clinical integration, addressing a critical gap in CMR accessibility and efficiency.
- Conditions
- Congenital Heart Diseases, Cardiac Diseases
- Keywords
- Free-running, Cine magnetic resonance imaging, Ventricular function, Multicenter, Multivendor, FISS (Fast- Interrupted Steady-State), Compressed sensing, Pragmatic clinical study
- Medical subject headings
- Heart Defects, Congenital, Heart Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with congenital heart disease | FAST-CMR will evaluate the technique's performance in complex, heterogeneous anatomy. | |
| Patients unable to perform breath-holding | including those with advanced heart failure, pulmonary hypertension, or chronic obstructive pulmonary disease (COPD), representing a subgroup where conventional breath-held CMR techniques are often suboptimal or not feasible. | |
| Other cardiovascular disease patients who are able to perform breath-holding | This group represents the standard patient population for whom conventional CMR is currently optimized. |
What is being measured
The primary outcome is the main question the study is designed to answer.
mean paired difference (bias) in left ventricular ejection fraction (LVEF) between 5D FISS-FRF and conventional 2D cine CMR
estimated with a two-sided 95% confidence interval within each pre-defined patient cohort. The study is designed to ensure that the half-width of this confidence interval does not exceed 1.25% LVEF per cohort.
Measured: Baseline (during study MRI acquisition)
Secondary outcomes (20)
Scan Efficiency
- Sequence acquisition time: scanner-reported acquisition duration for 5D FISS-FRF and conventional 2D cine imaging. This will include the timing of the necessary localizers specific to the imaging plane for each acquisition mode.
- Workflow time: elapsed time from initiation of cine planning to completion of cine acquisitions, including slice planning, patient instruction, rest between breath-holds, and repeated acquisitions when required.
Measured: Baseline (during study MRI acquisition)
Quantitative Image Quality
- Contrast ratio and endocardial-to-blood-pool interface sharpness between 5D FISS-FRF and conventional 2D cine.
Measured: Baseline (during study MRI acquisition)
Qualitative Image Quality
- Likert scale (0-4) consensus grading by ≥2 expert CMR readers blinded to images from both techniques.
Measured: Baseline (during study MRI acquisition)
Failure Rate
- Percentage of non-diagnostic or excluded scans.
Measured: Baseline (during study MRI acquisition)
Anatomical Coverage
- Extent of volumetric coverage of the entire heart and related great vessels.
Measured: Baseline (during study MRI acquisition)
Multiparametric Capability
- Presence of additional diagnostic insights from respiratory motion tracking of FRF.
Measured: Baseline (during study MRI acquisition)
Clinical Acceptability of LVEF Measurements (±5% Threshold)
- Exploratory analyses will assess whether observed agreement metrics are compatible with commonly used clinical acceptability thresholds (e.g., ±5% LVEF). These analyses are hypothesis-generating and intended to inform future confirmatory studies.
Measured: Baseline (during study MRI acquisition)
LV mass
Comparison between 5D FISS-FRF and 2D conventional cine
Measured: Baseline (during study MRI acquisition)
Regional wall motion abnormalities
assessed using a 4-point likert scale per AHA segment (normal, hypokinesia, akinesia, dyskinesia)
Measured: Baseline (during study MRI acquisition)
Left and right atrial volumes
maximum and minimum volumes and total atrial emptying fraction derived from conventional 2D cine long-axis views compared to 5D FISS-FRF
Measured: Baseline (during study MRI acquisition)
Agreement of Automated Ventricular Ejection Fraction Measurements (LVEF, RVEF)
Agreement of automatically post-processed ventricular ejection fraction measurements (LVEF, RVEF) derived from 5D FISS-FRF with (1) standard post-processing of 5D FISS-FRF and (2) standard post-processing of conventional 2D cine cardiac MRI. Agreement will be assessed using appropriate statistical metrics.
Measured: Baseline (during study MRI acquisition)
Agreement of Automated Ventricular Function Measurements (LVEDV, LVESV, LVSV, RVEDV, RVESV, RVSV)
Agreement of automatically post-processed ventricular function metrics (LVEDV, LVESV, LVSV, RVEDV, RVESV, RVSV) derived from 5D FISS-FRF with (1) standard post-processing of 5D FISS-FRF and (2) standard post-processing of conventional 2D cine cardiac MRI. Agreement will be assessed using appropriate statistical metrics.
Measured: Baseline (during study MRI acquisition)
Feasibility of AI-Based Image Reconstruction
Percentage of reconstructed datasets that are considered clinically usable based on predefined quality criteria.
Measured: Baseline (during study MRI acquisition)
Reconstruction Time
Comparison of reconstruction time between AI-based reconstruction and standard compressed sensing methods.
Measured: Baseline (during study MRI acquisition)
Accuracy of Ventricular Ejection Fraction Measurements
Comparison of left and right ventricular ejection fraction (LVEF, RVEF) between AI-based and standard reconstructions.
Measured: Baseline (during study MRI acquisition)
Accuracy of Ventricular Volume Measurements
Comparison of left and right ventricular end-diastolic volume (EDV), end-systolic volume (ESV), and stroke volume (SV) between AI-based and standard reconstructions.
Measured: Baseline (during study MRI acquisition)
Accuracy of Left Ventricular Mass Measurements
Comparison of left ventricular mass between AI-based and standard reconstructions.
Measured: Baseline (during study MRI acquisition)
Voxel-wise Image Similarity Between Reconstruction Methods
Image similarity assessed using structural similarity index measure (SSIM), peak signal-to-noise ratio (PSNR), and root mean squared error (RMSE).
Measured: Baseline (during study MRI acquisition)
Quantitative Image Quality
Contrast ratio and endocardial-to-blood-pool interface sharpness between reconstruction methods.
Measured: Baseline (during study MRI acquisition)
Qualitative Image Quality
Likert scale (0-4) consensus grading by ≥2 expert CMR readers blinded to images from both reconstruction methods.
Measured: Baseline (during study MRI acquisition)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 May 2026
- Study startJun 2026 (estimated)
- Primary completionJan 2028 (estimated)
- Study completionSep 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Congenital Heart DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 300 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Matthias Stuber
- Sponsor type
- University, hospital or other
- Collaborators
- Mayo Clinic, University of California, Los Angeles
- Responsible party
- Sponsor-investigator, Matthias Stuber, Centre Hospitalier Universitaire Vaudois
- Investigators
- Matthias Stuber, PhD, Principal investigator, CHUVTim Leiner, MD, PhD, Principal investigator, Mayo ClinicKim-Lien Nguyen, MD, Principal investigator, University of California, Los Angeles
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07613398
- Sponsor's protocol ID
- 2025-00923
- Other IDs
- 2025
- Acronym
- FAST-CMR
- Status last verified
- Apr 2026
- First submitted
- 27 Feb 2026
- Last updated
- 29 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Ogier AC, Baup S, Ilanjian G, Touray A, Rocca A, Banus J, Monton Quesada I, Nicoletti M, Ledoux JB, Richiardi J, Holtackers RJ, Yerly J, Stuber M, Hullin R, Rotzinger D, van Heeswijk RB. Cardiac function assessment with deep-learning-based automatic segmentation of free-running four-dimensional whole-heart cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2026 Summer;28(1):102677. doi: 10.1016/j.jocmr.2025.102677. Epub 2025 Dec 24.
PubMed 41453741Koktzoglou I, Edelman RR. Radial fast interrupted steady-state (FISS) magnetic resonance imaging. Magn Reson Med. 2018 Apr;79(4):2077-2086. doi: 10.1002/mrm.26881. Epub 2017 Aug 30.
PubMed 28856788Yerly J, Roy CW, Milani B, Eyre K, Raifee MJ, Stuber M. High on sparsity: Interbin compensation of cardiac motion for improved assessment of left-ventricular function using 5D whole-heart MRI. Magn Reson Med. 2025 Mar;93(3):975-992. doi: 10.1002/mrm.30323. Epub 2024 Oct 9.
PubMed 39385350Bastiaansen JAM, Piccini D, Di Sopra L, Roy CW, Heerfordt J, Edelman RR, Koktzoglou I, Yerly J, Stuber M. Natively fat-suppressed 5D whole-heart MRI with a radial free-running fast-interrupted steady-state (FISS) sequence at 1.5T and 3T. Magn Reson Med. 2020 Jan;83(1):45-55. doi: 10.1002/mrm.27942. Epub 2019 Aug 27.
PubMed 31452244Di Sopra L, Piccini D, Coppo S, Stuber M, Yerly J. An automated approach to fully self-gated free-running cardiac and respiratory motion-resolved 5D whole-heart MRI. Magn Reson Med. 2019 Dec;82(6):2118-2132. doi: 10.1002/mrm.27898. Epub 2019 Jul 18.
PubMed 31321816
Study at a glance
From the registry record, last updated by the sponsor on 29 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment and Validation of the Established Free-Running Framework for Cardiac Function by Magnetic Resonance Imaging (FAST-CMR): An International Multi-Center, Multi-Vendor Study at 1.5T
- ClinicalTrials.gov ID
- NCT07613398
- Acronym / sponsor ID
- FAST-CMR / 2025-00923
- Conditions
- Congenital Heart Diseases, Cardiac Diseases
- Keywords
- Free-running, Cine magnetic resonance imaging, Ventricular function, Multicenter, Multivendor, FISS (Fast- Interrupted Steady-State), Compressed sensing, Pragmatic clinical study
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Matthias StuberUniversity, hospital or other
- Collaborators
- Mayo Clinic, University of California, Los Angeles
- Study start
- Jun 2026 (estimated)
- Primary completion
- Jan 2028 (estimated)
- Study completion
- Sep 2030 (estimated)
- First posted
- 29 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This project aims to evaluate a new cardiac MRI technique called the Free-Running Framework (FRF), which could simplify and accelerate the process of acquiring cardiac images. The investigators want to verify whether this method can provide functional heart measurements comparable to those obtained with traditional methods. More specifically, the goal of the study is to compare the measurements obtained with FRF to those obtained with standard sequences, to ensure they match and that this new approach can be reliably used in clinical practice. The FRF technique works differently from standard cardiac MRI. In standard exams, patients are asked to hold their breath several times and small electrodes (ECG) are used to monitor the heartbeat during the scan. These steps are needed to get clearer images of the heart as it moves. With FRF, these steps are no longer necessary: the scan is performed while patients' breath normally and without ECG monitoring. In addition, standard MRI takes multiple 2D slices of the heart, one after another. The FRF method instead captures a 3D image of the entire heart in one go, which can improve the consistency of the exam and reduce errors when doctors analyze the images later. This is all possible because the FRF method records data continuously and then organizes the images afterward based on how participants heart and breathing were moving during the exam. This helps the imager to get clear images of the heart, even without breath-holding or ECG monitoring. This project is aimed at individuals with heart disease who require cardiac MRI exams to monitor their health status (age ≥ 18 years) and are able to clearly understand the instructions provided by the research team. The investigators have already conducted small-scale technical and feasibility studies using FRF. These studies have shown that FRF is easy to use, faster than traditional methods, and provides image quality comparable to standard imaging techniques. The investigators now wish to evaluate its use in a clinical setting. More specifically, the investigators need to verify that FRF provides the same essential diagnostic information as standard techniques, so that it can be reliably used in future patient care. A maximum of 300 participants will be included in the investigation of this MRI technique between 2026 and 2031. This is a multi-center study, conducted internationally across 18 centers.
This project is being carried out in compliance with Swiss legislation. The investigators follow all internationally recognized guidelines. The competent ethics committee has reviewed and approved this project.
Detailed description
Cardiovascular disease remains the leading cause of death in industrialized nations. While a range of diagnostic tools exists for cardiovascular disease detection and monitoring, magnetic resonance imaging (MRI) remains the only modality that enables a safe, non-invasive assessment of the heart without exposure to ionizing radiation. MRI allows for a comprehensive evaluation of cardiac anatomy, function, myocardial tissue characterization, and blood flow quantification, making it a powerful tool for cardiovascular diagnostics.
Despite strong clinical evidence supporting its utility, cardiac MRI (CMR) remains underutilized, primarily due to the length and complexity of a traditional CMR exam. Several factors contribute to the length and complexity of a standard CMR exam. First, a standard CMR protocol relies heavily on two-dimensional (2D) image acquisitions, each requiring manual slice planning by an experienced technologist-a process that is both time consuming and highly dependent on operator expertise. Second, traditional image acquisition requires electrocardiogram (ECG) triggering to synchronize with the cardiac cycle, requiring additional setup and potentially introducing errors if the ECG signal is suboptimal. Finally, most conventional sequences rely on repeated patient breath-holding to minimize respiratory motion artifacts, which can be particularly challenging for individuals with severe cardiovascular disease, congenital anomalies, or limited compliance. Even for highly skilled personnel, this process is timeconsuming and inefficient. Consequently, a significant portion of the patient's time in the scanner is spent on preparation and planning rather than actual image acquisition, leading to prolonged exam durations and increased healthcare costs.
Given these challenges, there is a strong need for simplified, automated, and time-efficient CMR acquisitions. In response to this challenge, the investigators research group has developed an innovative "free-running framework" (FRF)-a set of MRI methods that continuously acquire threedimensional (3D) image data across the entire cardiac cycle and throughout free breathing, irrespective of cardiac or respiratory motion. Unlike conventional CMR sequences that require separate, prospectively planned acquisitions for each imaging plane and time point, FRF employs continuous, self-navigated data acquisition. This eliminates the need for complex slice planning and enables retrospective reconstruction of cardiac motion, ensuring that imaging is both standardized and independent of user expertise. By leveraging advanced motion-resolved reconstruction algorithms developed by the investigators group, the investigators can derive both cardiac and respiratory motion from a single dataset, providing a fully automated, 3D whole-heart imaging approach.
Once diagnosed, patients with cardiac diseases often require lifelong monitoring and repeated imaging assessments to guide treatment decisions and evaluate disease progression. This makes a non-ionizing imaging modality like CMR admirable. Nonetheless, the prolonged scan durations and intricate manual planning associated with traditional CMR limit its accessibility and practical feasibility. By eliminating the need for slice planning and reducing scan complexity, FRF has the potential to significantly improve imaging for cardiac disease patients by:
- Standardizing imaging: producing user-independent results robust to anatomical variations.
- Reducing scan times: without compromising diagnostic information.
- Improving accessibility: enabling easier adoption in centers with less experienced technologists.
The feasibility of FRF has been demonstrated in experimental, pre-clinical, and small observational clinical studies, with no observed adverse effects. This study aims to evaluate its clinical feasibility and efficiency in real-world cardiac disease patients across multiple cardiac institutions, serving as a precursor for larger validation studies and eventual clinical implementation. This study will provide the first systematic clinical evaluation of 3D FRF across multiple cardiac institutions in cardiac disease patients, assessing both its technical feasibility and potential workflow benefits in a real-world setting. In particular, this study will:
- Evaluate whether diagnostic information from FRF matches or exceeds standard CMR.
- Assess the efficiency gains and the impact of automated, self-navigated imaging on scan duration and patient comfort.
If successful, this study will lay the groundwork for future multi-center validation clinical trial studies and eventual clinical integration, addressing a critical gap in CMR accessibility and efficiency.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Patients with congenital heart disease | – | –FAST-CMR will evaluate the technique's performance in complex, heterogeneous anatomy. |
| Patients unable to perform breath-holding | – | –including those with advanced heart failure, pulmonary hypertension, or chronic obstructive pulmonary disease (COPD), representing a subgroup where conventional breath-held CMR techniques are often suboptimal or not feasible. |
| Other cardiovascular disease patients who are able to perform breath-holding | – | –This group represents the standard patient population for whom conventional CMR is currently optimized. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- This study will prospectively include 300 patients (~15-20 per site) with known or suspected cardiac disease who are referred for a clinically indicated CMR scan as part of their routine clinical work-up.
Key inclusion criteria (4 listed)
- Diagnosed with cardiac disease of any complexity and scheduled for a clinical cardiac MRI on a clinical 1.5T MRI scanner
- Able to understand and provide written informed consent or, for minors, ability to provide assent with written consent from a parent/legal representative, per local law and site policy prior to the study
- Ability to undergo MRI without contraindications
- Agrees to be informed in the event of incidental findings
Key exclusion criteria (4 listed)
- Severe claustrophobia preventing MRI completion
- Presence of non-MRI compatible implants (e.g., pacemakers, certain metallic implants)
- Contraindications to the intravenous contrast agent
- Movement disorders or inability to remain still during the scan
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
mean paired difference (bias) in left ventricular ejection fraction (LVEF) between 5D FISS-FRF and conventional 2D cine CMR
Time frame: Baseline (during study MRI acquisition)
estimated with a two-sided 95% confidence interval within each pre-defined patient cohort. The study is designed to ensure that the half-width of this confidence interval does not exceed 1.25% LVEF per cohort.
20 secondary outcomes
Scan Efficiency
Time frame: Baseline (during study MRI acquisition)
Quantitative Image Quality
Time frame: Baseline (during study MRI acquisition)
Qualitative Image Quality
Time frame: Baseline (during study MRI acquisition)
Failure Rate
Time frame: Baseline (during study MRI acquisition)
Anatomical Coverage
Time frame: Baseline (during study MRI acquisition)
Multiparametric Capability
Time frame: Baseline (during study MRI acquisition)
Clinical Acceptability of LVEF Measurements (±5% Threshold)
Time frame: Baseline (during study MRI acquisition)
LV mass
Time frame: Baseline (during study MRI acquisition)
Regional wall motion abnormalities
Time frame: Baseline (during study MRI acquisition)
Left and right atrial volumes
Time frame: Baseline (during study MRI acquisition)
Agreement of Automated Ventricular Ejection Fraction Measurements (LVEF, RVEF)
Time frame: Baseline (during study MRI acquisition)
Agreement of Automated Ventricular Function Measurements (LVEDV, LVESV, LVSV, RVEDV, RVESV, RVSV)
Time frame: Baseline (during study MRI acquisition)
Feasibility of AI-Based Image Reconstruction
Time frame: Baseline (during study MRI acquisition)
Reconstruction Time
Time frame: Baseline (during study MRI acquisition)
Accuracy of Ventricular Ejection Fraction Measurements
Time frame: Baseline (during study MRI acquisition)
Accuracy of Ventricular Volume Measurements
Time frame: Baseline (during study MRI acquisition)
Accuracy of Left Ventricular Mass Measurements
Time frame: Baseline (during study MRI acquisition)
Voxel-wise Image Similarity Between Reconstruction Methods
Time frame: Baseline (during study MRI acquisition)
Quantitative Image Quality
Time frame: Baseline (during study MRI acquisition)
Qualitative Image Quality
Time frame: Baseline (during study MRI acquisition)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 May 2026.
- Background: PubMed 41453741Ogier AC, Baup S, Ilanjian G, Touray A, Rocca A, Banus J, Monton Quesada I, Nicoletti M, Ledoux JB, Richiardi J, Holtackers RJ, Yerly J, Stuber M, Hullin R, Rotzinger D, van Heeswijk RB. Cardiac function assessment with deep-learning-based automatic segmentation of free-running four-dimensional whole-heart cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2026 Summer;28(1):102677. doi: 10.1016/j.jocmr.2025.102677. Epub 2025 Dec 24.
- Background: PubMed 28856788Koktzoglou I, Edelman RR. Radial fast interrupted steady-state (FISS) magnetic resonance imaging. Magn Reson Med. 2018 Apr;79(4):2077-2086. doi: 10.1002/mrm.26881. Epub 2017 Aug 30.
- Background: PubMed 39385350Yerly J, Roy CW, Milani B, Eyre K, Raifee MJ, Stuber M. High on sparsity: Interbin compensation of cardiac motion for improved assessment of left-ventricular function using 5D whole-heart MRI. Magn Reson Med. 2025 Mar;93(3):975-992. doi: 10.1002/mrm.30323. Epub 2024 Oct 9.
- Background: PubMed 31452244Bastiaansen JAM, Piccini D, Di Sopra L, Roy CW, Heerfordt J, Edelman RR, Koktzoglou I, Yerly J, Stuber M. Natively fat-suppressed 5D whole-heart MRI with a radial free-running fast-interrupted steady-state (FISS) sequence at 1.5T and 3T. Magn Reson Med. 2020 Jan;83(1):45-55. doi: 10.1002/mrm.27942. Epub 2019 Aug 27.
- Background: PubMed 31321816Di Sopra L, Piccini D, Coppo S, Stuber M, Yerly J. An automated approach to fully self-gated free-running cardiac and respiratory motion-resolved 5D whole-heart MRI. Magn Reson Med. 2019 Dec;82(6):2118-2132. doi: 10.1002/mrm.27898. Epub 2019 Jul 18.
Related trials for Congenital Heart Diseases
Not yet recruiting
Autologous Thymus Transplant in Children With Congenital Heart Disease: A Pilot Study
Congenital Heart Disease (CHD)
RecruitingPhase 1
A Study of SGT-212 Gene Therapy in Friedreich's Ataxia
Friedreich's Ataxia (FA)
RecruitingObservational study
The CACHE Study: Coronary Artery Care in HaEmophilia
Haemophilia, Cardiovascular Diseases
RecruitingObservational study
Essen Amyloidosis Registry
Amyloidosis; Systemic, Amyloidosis Cardiac
RecruitingPhase 3
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
Turner Syndrome, Short Stature Homeobox Gene Mutation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Matthias Stuber, PhD principal investigator
CHUV
Tim Leiner, MD, PhD principal investigator
Mayo Clinic
Kim-Lien Nguyen, MD principal investigator
University of California, Los Angeles
20 sites in 10 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Congenital Heart Diseases and Cardiac Diseases, run by Matthias Stuber at 20 sites in 10 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 20 sites in United States, Germany, Australia, Colombia, Italy and 5 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Katerina Eyre, PhD (+41213147513, katerina.eyre@chuv.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
mean paired difference (bias) in left ventricular ejection fraction (LVEF) between 5D FISS-FRF and conventional 2D cine CMR (time frame: Baseline (during study MRI acquisition)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07613398, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2026.